Keyphrases
Chimeric Antigen Receptor T Cells (CAR-T)
100%
Osteoclast
64%
Overall Survival
46%
Chimeric Antigen Receptor T-cell Therapy
43%
Pancreatic Cancer
37%
Tumor
35%
Radiation Therapy
34%
Cell Therapy
33%
Glucose Uptake
33%
AKT Inhibitor
33%
Low-dose Radiation
33%
Mammalian Target of Rapamycin (mTOR)
33%
Cervical Cancer
33%
Cell Death
33%
Head-and-neck Cancer
33%
Estrogen
33%
Osteoporosis
33%
T Cells
29%
Osteoclast Function
24%
Interleukin-17 (IL-17)
23%
Internal Mammary Lymph Node
23%
CD19
22%
Neoantigen
22%
Salvage Radiotherapy
22%
Antigen Escape
22%
Natural Killer Cells
22%
Breast Cancer
22%
Regional Failure
21%
Receptor Activator of nuclear factor-κB Ligand (RANKL)
20%
Cancer Immunotherapy
20%
Non-Hodgkin Lymphoma
20%
Cytoskeleton
20%
Macrophages
19%
Locoregional Recurrence
19%
Tumor Microenvironment
19%
Clinical Experience
19%
Re-irradiation
18%
Osteoclastic Bone Resorption
18%
Breast Cancer Patients
17%
Feasibility Outcomes
16%
Immune Cells
16%
Author Names
16%
Cell Salvage
16%
Lab Study
16%
CAR T-cell Therapy
16%
Genetic Modification
16%
Future Role
16%
Transcriptional States
16%
Current Role
16%
Tumor Resistance
16%
Medicine and Dentistry
Radiation Therapy
82%
Overall Survival
53%
Chimeric Antigen Receptor T-Cell
50%
Breast Cancer
44%
Recurrent Disease
41%
Chimeric Antigen Receptor
38%
Neoplasm
33%
Glucose Uptake
33%
Cell Death
33%
Low Drug Dose
33%
Head and Neck Cancer
33%
Cervical Cancer
33%
mTOR Signaling
33%
Malignant Neoplasm
31%
Disease
30%
Cell Therapy
28%
Chimeric Antigen Receptor T-Cell Immunotherapy
27%
Immunotherapy
24%
Internal Mammary Node
23%
Macrophage
22%
Pancreas Cancer
20%
Re-Irradiation
18%
Amyloid Plaque
16%
Metastatic Breast Cancer
16%
Alzheimer's Disease
16%
Metastatic Carcinoma
16%
Immunocompetent Cell
16%
Natural Killer Cell Response
16%
Rectum Carcinoma
16%
Head and Neck Squamous Cell Carcinoma
16%
Adaptive Radiotherapy
16%
Tumor Resistance
16%
Tumor Differentiation
16%
CAR T-cell therapy
16%
Cell Viability
16%
Osteoclast
16%
Radiation Necrosis
16%
Intensity Modulated Radiation Therapy
16%
Radioimmunotherapy
16%
Nasopharynx Carcinoma
16%
Tumor Cell
15%
Osteoclastogenesis
13%
T Cell
13%
Tumor Microenvironment
11%
Immune Response
11%
Solid Malignant Neoplasm
11%
In Vitro
10%
Clinical Trial
10%
Distant Metastasis
10%
Natural Killer Cell
10%
